A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine.

摘要: Patient-derived xenograft (PDX) models are increasingly being used in oncology drug development because they offer greater predictive value than traditional cell line models. Using novel tools to critique model validity and reliability we performed a systematic review identify all original publications describing the derivation of PDX colon, prostate, breast lung cancer. Validity was defined as ability recapitulate disease interest. The study protocol registered with Collaborative Approach Meta-Analysis Review Animal Data from Experimental Studies (CAMARADES). Searches were Embase, MEDLINE Pubmed up July 2017. A narrative data synthesis performed. We identified 105 studies validations; 29 for breast, 25 lung, 23 prostate 4 multiple tissues. 133 excluded did not perform any validation experiments despite deriving PDX. Only one reported following ARRIVE guidelines; developed improve standard reporting animal experimentation. Remarkably, half (52%) (50%) judged have high concern, contrast 16% colon 28% studies. criteria that most commonly failed (evidence contrary) were: tissue origin proven histology comparable parental tumour. Overall, categorized unclear or more conditions reported, researchers provide proportion their For example, failure demonstrate origin, response care agents exclude lymphoma. Validation potential reproducibility, reduce waste research increase success translational